Fernwood Investment Management LLC continued to hold its stake in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, Holdings Channel reports. The firm owned 43,774 shares of the medical equipment provider’s stock at the end of the second quarter. Fernwood Investment Management LLC’s holdings in Boston Scientific Corporation were worth $1,213,000 as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. Toronto Dominion Bank boosted its stake in shares of Boston Scientific Corporation by 56.7% in the first quarter. Toronto Dominion Bank now owns 367,924 shares of the medical equipment provider’s stock valued at $9,150,000 after buying an additional 133,121 shares during the period. Koch Industries Inc. bought a new position in Boston Scientific Corporation during the first quarter valued at $307,000. Bellevue Group AG increased its position in Boston Scientific Corporation by 4.0% in the first quarter. Bellevue Group AG now owns 572,000 shares of the medical equipment provider’s stock valued at $14,226,000 after buying an additional 22,000 shares in the last quarter. Principal Financial Group Inc. increased its position in Boston Scientific Corporation by 1.7% in the first quarter. Principal Financial Group Inc. now owns 1,983,944 shares of the medical equipment provider’s stock valued at $49,340,000 after buying an additional 33,763 shares in the last quarter. Finally, Morgan Stanley increased its position in Boston Scientific Corporation by 63.8% in the first quarter. Morgan Stanley now owns 3,744,380 shares of the medical equipment provider’s stock valued at $93,124,000 after buying an additional 1,458,906 shares in the last quarter. 91.62% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Corporation (NYSE:BSX) opened at 26.47 on Wednesday. Boston Scientific Corporation has a 52-week low of $19.67 and a 52-week high of $28.51. The stock’s 50 day moving average price is $27.26 and its 200-day moving average price is $26.12. The company has a market cap of $36.32 billion, a P/E ratio of 47.35 and a beta of 1.09.

Boston Scientific Corporation (NYSE:BSX) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The business had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the previous year, the firm posted $0.27 earnings per share. The company’s revenue was up 6.2% on a year-over-year basis. On average, equities analysts predict that Boston Scientific Corporation will post $1.26 earnings per share for the current fiscal year.

WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/fernwood-investment-management-llc-holds-position-in-boston-scientific-corporation-bsx/1494503.html.

Several equities analysts have recently weighed in on the company. J P Morgan Chase & Co reissued an “overweight” rating and set a $31.00 target price (up previously from $27.00) on shares of Boston Scientific Corporation in a research report on Wednesday, June 28th. Zacks Investment Research downgraded Boston Scientific Corporation from a “buy” rating to a “hold” rating in a research report on Thursday, June 29th. Royal Bank Of Canada reissued a “buy” rating and set a $31.00 target price on shares of Boston Scientific Corporation in a research report on Wednesday, July 12th. Wells Fargo & Company reissued an “outperform” rating and set a $31.00 target price (up previously from $29.50) on shares of Boston Scientific Corporation in a research report on Friday, June 16th. Finally, BidaskClub raised Boston Scientific Corporation from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $30.06.

In other news, SVP John Bradley Sorenson sold 2,100 shares of Boston Scientific Corporation stock in a transaction on Monday, July 31st. The stock was sold at an average price of $27.15, for a total value of $57,015.00. Following the completion of the sale, the senior vice president now directly owns 18,880 shares of the company’s stock, valued at $512,592. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Daniel J. Brennan sold 92,158 shares of Boston Scientific Corporation stock in a transaction on Tuesday, July 11th. The shares were sold at an average price of $27.48, for a total value of $2,532,501.84. Following the completion of the sale, the chief financial officer now directly owns 235,421 shares of the company’s stock, valued at $6,469,369.08. The disclosure for this sale can be found here. Insiders sold 207,625 shares of company stock valued at $5,686,383 over the last ninety days. Insiders own 0.74% of the company’s stock.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.